Search
Solcitinib
go.drugbank.com/drugs/DB19856InvestigationalSolcitinib is under investigation in clinical trial NCT01777256 (An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184).
Levcromakalim
go.drugbank.com/drugs/DB21154InvestigationalLevcromakalim is under investigation in clinical trial NCT04853797 (Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM)).
Velufenacin
go.drugbank.com/drugs/DB21473InvestigationalVelufenacin is under investigation in clinical trial NCT05282069 (A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder).
Radequinil
go.drugbank.com/drugs/DB19722InvestigationalRadequinil is under investigation in clinical trial NCT00359944 (Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease).
Cyamemazine
go.drugbank.com/drugs/DB09000ExperimentalCyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).
VPM4001
go.drugbank.com/drugs/DB05089ExperimentalIt consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete interferon-γ and interleukin-2 (LNCaP/IL-2/IFN-γ).
ATG-101
go.drugbank.com/drugs/DB17162InvestigationalATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors
Lemzoparlimab
go.drugbank.com/drugs/DB17572InvestigationalLemzoparlimab is under investigation in clinical trial NCT04912063 (Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or
L-cysteic acid
go.drugbank.com/drugs/DB03661ExperimentalIt occurs normally in the outer part of the sheep's fleece, where the wool is exposed to light and weather.
QazCovid-in
go.drugbank.com/drugs/DB16441InvestigationalIt demonstrated high efficacy, safety, and immunogenicity at 96% in initial Phase I and II trials (NCT04530357), and will now be undergoing upcoming Phase III trials[L30633, L30638].